Startups, BioPharma

Corporate venture investment growing in the life sciences

The top sectors for corporate venture deals are software, energy and biotechnology, according to a new PwC and NCVA MoneyTree report.

There’s been a significant uptick in corporate venture deals across all sectors, a third quarter MoneyTree report shows – with biotechnology shaping up as the third most attractive industry to corporate investors.

Indeed, biotechnologies attracted $1 billion in 106 deals, making up 15.6 percent of all corporate venture investment. Indeed, corporates deployed $2.3 billion in 240 deals to various startups, making up 14.1 percent of all venture dollars invested and 21.5 percent of all deals.

“Participating in over a fifth of all venture deals for the quarter and year, corporate venture activity continues to pick up steam,” Bobby Franklin, president and CEO of the National Venture Capitalists Association, said in a statement.

This is most pronounced in the software and energy sectors. Biotechnology and the broader life sciences industry comes next – with $1.2 billion invested in 140 deals when including medical device companies.

[Image courtesy of Flickr user AMagill]